Allogeneic bone marrow-derived mesenchymal stromal cell therapy - Orbsen Therapeutics

Drug Profile

Allogeneic bone marrow-derived mesenchymal stromal cell therapy - Orbsen Therapeutics


Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Orbsen Therapeutics
  • Developer Mario Negri Institute for Pharmacological Research
  • Class Stem cell therapies; Uroprotectives
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Diabetic nephropathies

Most Recent Events

  • 11 Dec 2017 Phase-I/II clinical trials in Diabetic nephropathies in United Kingdom, Italy, Ireland (IV) (NCT02585622)
  • 08 Aug 2017 Orbsen Therapeutics has patent protection for mesenchymal stromal cell therapy in USA, Canada, Australia, Japan, Russia, India and China before August 2017 (Orbsen Therapeutics website, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top